A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement.
Holm Schneider, Christine Schweikl, Florian Faschingbauer...
https://pubmed.ncbi.nlm.nih.gov/37108325/Actively Recruiting
Led by EspeRare Foundation · Updated on 2025-04-30
20
Participants Needed
8
Research Sites
304 weeks
Total Duration
This clinical trial investigates the use of ER004 as a prenatal treatment for male fetuses diagnosed with X-linked hypohidrotic ectodermal dysplasia XLHED, a rare developmental disorder affecting skin, teeth, and sweat glands caused by mutations in the ectodysplasin A gene. The study is an open-label, prospective, non-randomized Phase 2 trial conducted internationally across multiple centers, aiming to confirm the safety and effectiveness of ER004 administered before birth. This trial addresses a critical unmet medical need since current treatments only manage symptoms without correcting the underlying cause. ER004 is a biologic protein designed to replace the missing EDA1 protein in affected individuals. The treatment involves three intra-amniotic injections given approximately three weeks apart starting from the 26th week of pregnancy, dosed based on estimated fetal weight. The trial includes a genotype-matched control group for comparison. The main study phase assesses efficacy and safety up to 6 months after birth, with a long-term follow-up extending assessments up to 5 years of age. Participants and their mothers undergo various evaluations including sweat volume measurements at 6 months, dental development, sweat pore density, ocular surface assessments, and monitoring for adverse events throughout the study period. Mothers are followed for safety up to one month after delivery. The trial compares treated subjects sweating ability to that of untreated relatives or matched controls. The extensive follow-up includes assessments of hospitalizations, eczema, salivation, and ocular health, ensuring comprehensive monitoring over five years.
CONDITIONS
Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia
A
Agnes Jaulent
M
Marlène Guiraud
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
EspeRare Foundation
Lead Sponsor
Pierre Fabre Medicament
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Prenatal ER004 (Ectodysplasin A1 Replacement) | Conventional Postnatal Management (Supportive Care) |
|---|---|---|
| What it is | A synthetic Ectodysplasin A1 (ER004) protein is injected into the amniotic fluid during pregnancy. This approach aims to replace the missing EDA1 protein in male fetuses with XLHED and address the underlying disease mechanism before birth. | Supportive and symptomatic treatments started after birth, tailored to an individual's symptoms, remain the established approach. This may include hydration measures, skin care, temperature management, dental care, and eye support. No disease-modifying treatment is given prenatally. |
| Role in this study | All eligible study fetuses received ER004 injections during gestation as the investigational intervention. | Conventional postnatal care was not given as a randomized or trial control arm; it represents external current practice for similar patients not receiving prenatal therapy. |
| Primary use | Intended to correct the underlying cause of XLHED by delivering functional EDA1 protein before birth to improve the development of sweat glands, teeth, and other ectodermal structures. | Manages symptoms after birth, such as hypohidrosis, dry eyes, dental problems, and heat intolerance, using supportive and preventive therapies. Does not address the underlying protein deficiency. |
| How it is given or performed | ER004 is injected into the amniotic fluid in three separate procedures during gestational weeks 26 to 31 (each about three weeks apart), based on fetal estimated weight. | Supportive care is started after birth and may involve ongoing pediatric assessment and interventions as needed, adjusted to the child's symptoms over time. |
| Evidence status | Early clinical investigations, including open-label and observational studies, suggest prenatal ER004 can increase postnatal sweat gland development and function, but large-scale randomized evidence is not yet available and the current trial is ongoing. | Symptomatic management improves comfort and reduces complications, but does not prevent core aspects of XLHED such as hypohidrosis, dental agenesis, or ocular issues. |
| Important limitations | Experience with prenatal ER004 is limited to small studies and ongoing trials. The procedure requires specialized prenatal diagnosis, maternal intervention, and has associated procedural risks. Long-term safety and effect durability continue to be studied. | Supports physical health and quality of life but does not prevent disease complications or restore normal development of affected structures. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 6 weeks
Participants receive 3 intra-amniotic injections of ER004, each approximately 3 weeks apart starting from gestational week 26.
3 treatment visits (in-person)
Duration - Up to 6 months after birth
Participants are followed to assess efficacy and safety up to 6 months of age; mothers are monitored for safety up to 1 month after delivery.
Multiple visits during the first 6 months of age
Duration - Up to 5 years
Participants are monitored for long-term efficacy and safety outcomes up to 5 years of age.
Periodic visits up to 5 years of age
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Holm Schneider, Christine Schweikl, Florian Faschingbauer...
https://pubmed.ncbi.nlm.nih.gov/37108325/Holm Schneider, Florian Faschingbauer, Sonia Schuepbach-Mallepell...
https://pubmed.ncbi.nlm.nih.gov/29694819/Holm Schneider, Smail Hadj-Rabia, Florian Faschingbauer...
https://pubmed.ncbi.nlm.nih.gov/36672894/EspeRare Foundation
Lead Sponsor
Pierre Fabre Medicament
Collaborating Sponsor